https://news.medxy.ai/zh/dysphagia-surgery-outcomes/Medxy AIzh2026-09-23T08:54:40-07:00衰弱是否会影响环咽肌功能障碍手术结局？——优化患者筛选与预期管理 https://news.medxy.ai/ja/pharyngeal-muscle-frailty/Medxy AIja2026-09-23T08:54:21-07:00輪状咽頭筋機能障害における手術転帰予測因子としてのフレイル：患者選択と期待値設定の最適化 https://news.medxy.ai/vi/surgery-outcomes-prediction/Medxy AIvi2026-09-23T08:54:01-07:00Suy yếu có dự báo kết quả phẫu thuật trong rối loạn chức năng cơ nhẫn hầu không? Tối ưu lựa chọn bệnh nhân và kỳ vọng điều trị https://news.medxy.ai/frailty-as-a-predictor-of-surgical-outcomes-in-cricopharyngeus-muscle-dysfunction-enhancing-patient-selection-and-expectations/Medxy AIen2026-09-23T08:53:43-07:00Frailty as a Predictor of Surgical Outcomes in Cricopharyngeus Muscle Dysfunction: Enhancing Patient Selection and Expectations https://news.medxy.ai/zh/chronic-rhinosinusitis-pathology/Medxy AIzh2026-09-23T08:53:02-07:00鼻内物质使用相关慢性鼻-鼻窦炎的组织病理学新认识：对临床管理的启示 https://news.medxy.ai/ja/77156-2/Medxy AIja2026-09-23T08:52:44-07:00鼻腔内物質に関連する慢性鼻副鼻腔炎の組織病理学的知見：臨床管理への示唆 https://news.medxy.ai/vi/chronic-rhinosinusitis-findings/Medxy AIvi2026-09-23T08:52:24-07:00Những phát hiện mô bệnh học trong viêm mũi xoang mạn tính liên quan đến sử dụng chất qua đường mũi: hàm ý cho quản lý lâm sàng https://news.medxy.ai/histopathologic-insights-in-chronic-rhinosinusitis-linked-to-intranasal-substance-use-implications-for-clinical-management/Medxy AIen2026-09-23T08:52:05-07:00Histopathologic Insights in Chronic Rhinosinusitis Linked to Intranasal Substance Use: Implications for Clinical Management https://news.medxy.ai/zh/environmental-impact-surgery/Medxy AIzh2026-09-23T08:51:28-07:00环境负担如何影响手术结局：揭开隐匿的健康差异 https://news.medxy.ai/ja/environmental-impact-surgery-2/Medxy AIja2026-09-23T08:51:14-07:00環境負荷は外科成績にどう影響するのか――見えにくい格差を読み解く https://news.medxy.ai/vi/environmental-burden-surgery-impact/Medxy AIvi2026-09-23T08:50:55-07:00Gánh nặng môi trường và tác động lên kết cục phẫu thuật: hé lộ những chênh lệch ẩn giấu https://news.medxy.ai/environmental-burden-and-its-influence-on-surgical-outcomes-unveiling-the-hidden-disparities/Medxy AIen2026-09-23T08:50:36-07:00Environmental Burden and Its Influence on Surgical Outcomes: Unveiling the Hidden Disparities https://news.medxy.ai/zh/automated-gastrectomy-quality/Medxy AIzh2026-09-23T08:49:57-07:00远端胃切除术质量评估再升级：基于计算机视觉的质量关键视野自动化判读 https://news.medxy.ai/ja/gastrectomy-quality-evaluation/Medxy AIja2026-09-23T08:49:39-07:00遠位胃切除術の手術品質評価を前進させる：Computer Vision による Critical View of Quality の自動解析 https://news.medxy.ai/vi/surgical-quality-assessment-2/Medxy AIvi2026-09-23T08:49:21-07:00Nâng tầm đánh giá chất lượng phẫu thuật trong cắt dạ dày xa: Đánh giá tự động Critical View of Quality bằng computer vision https://news.medxy.ai/advancing-surgical-quality-assessment-in-distal-gastrectomy-automated-evaluation-of-the-critical-view-of-quality-using-computer-vision/Medxy AIen2026-09-23T08:49:02-07:00Advancing Surgical Quality Assessment in Distal Gastrectomy: Automated Evaluation of the Critical View of Quality Using Computer Vision https://news.medxy.ai/zh/neurotensin-receptor1/Medxy AIzh2026-09-23T08:48:26-07:00神经降压素受体1：驱动结直肠癌免疫排斥与不良预后的关键因素 https://news.medxy.ai/ja/neurotensin-receptor1-colon-cancer/Medxy AIja2026-09-23T08:48:09-07:00ニューロテンシン受容体1が切り拓く大腸がんの免疫排除機構と予後不良の鍵 https://news.medxy.ai/vi/neurotensin-receptor-1/Medxy AIvi2026-09-23T08:47:51-07:00Thụ thể Neurotensin 1: Động lực then chốt của hiện tượng loại trừ miễn dịch và tiên lượng xấu trong ung thư đại trực tràng https://news.medxy.ai/neurotensin-receptor-1-a-key-driver-of-immune-exclusion-and-poor-prognosis-in-colorectal-cancer/Medxy AIen2026-09-23T08:47:32-07:00Neurotensin Receptor 1: A Key Driver of Immune Exclusion and Poor Prognosis in Colorectal Cancer https://news.medxy.ai/zh/early-treatment-severe-preeclampsia/Medxy AIzh2026-09-23T08:46:50-07:00早发型重度子痫前期中降压治疗升级：期待治疗期间母体风险的动态标志 https://news.medxy.ai/ja/early-severe-preeclampsia/Medxy AIja2026-09-23T08:46:33-07:00早発性重症子癇前症における降圧治療増強：待機的管理中の母体リスクを示す動的マーカー https://news.medxy.ai/vi/early-pre-eclampsia-treatment/Medxy AIvi2026-09-23T08:46:13-07:00Tăng cường điều trị hạ huyết áp trong tiền sản giật khởi phát sớm có đặc điểm nặng: chỉ dấu động về nguy cơ mẹ trong xử trí theo dõi chờ đợi https://news.medxy.ai/escalating-antihypertensive-therapy-in-early-onset-severe-preeclampsia-dynamic-marker-of-maternal-risk-during-expectant-management/Medxy AIen2026-09-23T08:45:53-07:00Escalating Antihypertensive Therapy in Early-Onset Severe Preeclampsia: Dynamic Marker of Maternal Risk During Expectant Management https://news.medxy.ai/laparoscopic-modified-davydovs-technique-for-vaginoplasty-operative-steps-and-technical-pearls/Medxy AIen2026-09-23T08:45:15-07:00Laparoscopic Modified Davydov’s Technique for Vaginoplasty: Operative Steps and Technical Pearls https://news.medxy.ai/zh/ontario-hysterectomy-trends/Medxy AIzh2026-09-23T08:44:39-07:00安大略省门诊子宫切除术的上升趋势及临床结局：基于人群的分析 https://news.medxy.ai/ja/77114-2/Medxy AIja2026-09-23T08:44:23-07:00オンタリオ州における外来子宮摘出術の増加傾向と臨床的転帰：集団ベースの解析 https://news.medxy.ai/vi/outpatient-hysterectomy-ontario/Medxy AIvi2026-09-23T08:44:05-07:00Cắt tử cung ngoại trú tại Ontario tăng nhanh cùng kết cục lâm sàng khả quan: phân tích dựa trên quần thể https://news.medxy.ai/rising-trends-and-clinical-outcomes-of-outpatient-hysterectomy-in-ontario-a-population-based-analysis/Medxy AIen2026-09-23T08:43:47-07:00Rising Trends and Clinical Outcomes of Outpatient Hysterectomy in Ontario: A Population-Based Analysis https://news.medxy.ai/zh/microbiome-necrotizing-enterocolitis/Medxy AIzh2026-09-23T08:43:10-07:00坏死性小肠结肠炎中的微生物差异机制与预测特征：肠道噬菌体与细菌耐药组的作用 https://news.medxy.ai/ja/necrotizing-enterocolitis-mechanisms/Medxy AIja2026-09-23T08:42:49-07:00壊死性腸炎における微生物機序の分岐と予測シグネチャー：腸内ファージと細菌レジストームの役割 https://news.medxy.ai/vi/77103-2/Medxy AIvi2026-09-23T08:42:25-07:00Sự phân hóa cơ chế vi sinh và các dấu ấn dự báo trong bệnh viêm ruột hoại tử: Vai trò của thể thực khuẩn đường ruột và hệ gen kháng thuốc của vi khuẩn (resistome) https://news.medxy.ai/divergent-microbial-mechanisms-and-predictive-signatures-in-necrotising-enterocolitis-the-role-of-gut-phages-and-bacterial-resistomes/Medxy AIen2026-09-23T08:42:03-07:00Divergent Microbial Mechanisms and Predictive Signatures in Necrotising Enterocolitis: The Role of Gut Phages and Bacterial Resistomes https://news.medxy.ai/zh/chronic-hepatitis-b/Medxy AIzh2026-09-23T08:41:16-07:00重新审视慢性乙型肝炎的免疫耐受期：RADICAL联盟揭示高转归率及其临床启示 https://news.medxy.ai/ja/chronic-hepatitis-b-2/Medxy AIja2026-09-23T08:40:55-07:00慢性B型肝炎の免疫寛容期を再考する：免疫活性病態への高い移行率とRADICAL consortiumが示す臨床的示唆 https://news.medxy.ai/vi/immune-tolerance-hepatitis-b/Medxy AIvi2026-09-23T08:40:33-07:00Xem xét lại pha dung nạp miễn dịch trong viêm gan B mạn tính: Tỷ lệ chuyển cao sang bệnh hoạt động miễn dịch và ý nghĩa lâm sàng từ liên minh RADICAL https://news.medxy.ai/reevaluating-immune-tolerant-phase-in-chronic-hepatitis-b-high-transition-rates-to-immune-active-disease-and-clinical-implications-from-the-radical-consortium/Medxy AIen2026-09-23T08:40:14-07:00Reevaluating Immune Tolerant Phase in Chronic Hepatitis B: High Transition Rates to Immune Active Disease and Clinical Implications from the RADICAL Consortium https://news.medxy.ai/zh/epilepsy-cause-evaluation/Medxy AIzh2026-09-23T08:39:34-07:00优化癫痫持续状态后的病因学评估：来自ICTAL登记研究的诊断获益与治疗启示 https://news.medxy.ai/ja/optimize-epilepsy-diagnosis/Medxy AIja2026-09-23T08:39:17-07:00けいれん重積状態後の病因検索を最適化する：ICTALレジストリが示す診断的有用性と治療への影響 https://news.medxy.ai/vi/epilepsy-investigation-optimization/Medxy AIvi2026-09-23T08:38:55-07:00Tối ưu hóa thăm dò căn nguyên sau trạng thái động kinh: Giá trị chẩn đoán và ý nghĩa điều trị từ sổ đăng ký ICTAL https://news.medxy.ai/optimizing-etiologic-investigations-after-status-epilepticus-diagnostic-yield-and-therapeutic-implications-from-the-ictal-registry/Medxy AIen2026-09-23T08:38:35-07:00Optimizing Etiologic Investigations After Status Epilepticus: Diagnostic Yield and Therapeutic Implications from the ICTAL Registry https://news.medxy.ai/ja/77090-2/Medxy AIja2026-09-23T08:37:32-07:00アルツハイマー病におけるタウPET病期分類のための統合的目視読影フレームワーク https://news.medxy.ai/vi/harmonious-image-reading/Medxy AIvi2026-09-23T08:37:12-07:00Một khung đọc hình ảnh hài hòa để phân giai đoạn Tau PET trong bệnh Alzheimer https://news.medxy.ai/a-harmonized-visual-reading-framework-for-tau-pet-staging-in-alzheimer-disease/Medxy AIen2026-09-23T08:36:54-07:00A Harmonized Visual Reading Framework for Tau PET Staging in Alzheimer Disease https://news.medxy.ai/ja/quantitative-insights/Medxy AIja2026-09-23T08:34:57-07:00縦断的システムモデリングで読み解くチルゼパチドとセマグルチドの定量的知見 https://news.medxy.ai/vi/tirzepatide-semaglutide-power/Medxy AIvi2026-09-23T08:34:40-07:00Tiết lộ sức mạnh của Tirzepatide và Semaglutide qua mô hình hệ thống dọc https://news.medxy.ai/quantitative-insights-into-tirzepatide-and-semaglutide-using-longitudinal-systems-modeling/Medxy AIen2026-09-23T08:34:22-07:00Quantitative Insights into Tirzepatide and Semaglutide Using Longitudinal Systems Modeling https://news.medxy.ai/zh/77077-2/Medxy AIzh2026-09-23T08:33:44-07:00PPARγ激动剂与GLP-1受体激动剂在中枢神经系统胰岛素抵抗中的作用 https://news.medxy.ai/ja/brain-metabolism-biomarkers/Medxy AIja2026-09-23T08:33:23-07:00神経由来細胞外小胞バイオマーカーから読む脳代謝：CNSインスリン抵抗性におけるPPARγ作動薬とGLP1受容体作動薬の役割 https://news.medxy.ai/vi/neuron-exosome-biomarkers/Medxy AIvi2026-09-23T08:32:59-07:00Dấu ấn sinh học từ túi ngoại bào nguồn gốc neuron: PPARγ và chất chủ vận thụ thể GLP1 điều biến chuyển hóa não trong kháng insulin của CNS https://news.medxy.ai/brain-metabolism-insights/Medxy AIen2026-09-23T08:32:37-07:00Insights from Neuron-Derived Extracellular Vesicle Biomarkers: PPARγ and GLP1 Receptor Agonists Modulate Brain Metabolism in CNS Insulin Resistance https://news.medxy.ai/zh/pediatric-thyroid-cancer/Medxy AIzh2026-09-23T08:31:45-07:00儿童分化型甲状腺癌：来自儿童与青少年甲状腺联盟的侵袭性疾病预测因素及治疗结局洞见 https://news.medxy.ai/ja/pediatric-thyroid-cancer-2/Medxy AIja2026-09-23T08:31:28-07:00小児分化型甲状腺癌：CATCが示す浸潤性病変の予測因子と治療成績 https://news.medxy.ai/vi/differentiated-thyroid-cancer-children/Medxy AIvi2026-09-23T08:31:06-07:00Ung thư tuyến giáp biệt hóa ở trẻ em: phát hiện từ Child and Adolescent Thyroid Consortium về các yếu tố dự báo bệnh xâm lấn và kết quả điều trị https://news.medxy.ai/pediatric-differentiated-thyroid-carcinoma-insights-from-the-child-and-adolescent-thyroid-consortium-on-invasive-disease-predictors-and-treatment-outcomes/Medxy AIen2026-09-23T08:30:48-07:00Pediatric Differentiated Thyroid Carcinoma: Insights from the Child and Adolescent Thyroid Consortium on Invasive Disease Predictors and Treatment Outcomes https://news.medxy.ai/zh/type-1-diabetes-risk/Medxy AIzh2026-09-23T08:30:08-07:001型糖尿病发病年龄越早，死亡与并发症风险越高：来自瑞典全国队列的研究启示 https://news.medxy.ai/ja/type-1-diabetes-age-onset/Medxy AIja2026-09-23T08:29:50-07:001型糖尿病は何歳で発症したかが予後を左右する：スウェーデン全国コホートが示す死亡・臓器合併症への影響 https://news.medxy.ai/vi/type-1-diabetes-age/Medxy AIvi2026-09-23T08:29:28-07:00Tuổi khởi phát đái tháo đường týp 1: yếu tố quyết định tiên lượng tử vong và biến chứng cơ quan từ dữ liệu đoàn hệ toàn quốc Thụy Điển https://news.medxy.ai/impact-of-age-at-type-1-diabetes-onset-on-mortality-and-organ-complications-insights-from-a-nationwide-swedish-cohort/Medxy AIen2026-09-23T08:29:07-07:00Impact of Age at Type 1 Diabetes Onset on Mortality and Organ Complications: Insights from a Nationwide Swedish Cohort https://news.medxy.ai/zh/empagliflozin-cv-benefits/Medxy AIzh2026-09-23T08:28:24-07:00恩格列净在2型糖尿病不同患者亚组中均显示一致的心血管获益：EMPRISE真实世界研究启示 https://news.medxy.ai/ja/empagliflozin-cv-benefits-2/Medxy AIja2026-09-23T08:28:04-07:00エンパグリフロジンは2型糖尿病の多様な患者集団で一貫した心血管利益を示す：EMPRISEリアルワールド研究からの知見 https://news.medxy.ai/vi/77045-2/Medxy AIvi2026-09-23T08:27:44-07:00Empagliflozin đã cho thấy lợi ích tim mạch nhất quán trên các phân nhóm bệnh nhân đái tháo đường tuýp 2 khác nhau https://news.medxy.ai/empagliflozin-demonstrates-uniform-cardiovascular-benefits-across-diverse-patient-subgroups-in-type-2-diabetes-insights-from-the-emprise-real-world-study/Medxy AIen2026-09-23T08:27:24-07:00Empagliflozin Demonstrates Uniform Cardiovascular Benefits Across Diverse Patient Subgroups in Type 2 Diabetes: Insights from the EMPRISE Real-World Study https://news.medxy.ai/zh/ttn-truncation-screening/Medxy AIzh2026-09-23T08:26:43-07:00携带TTN截断变异亲属的个体化筛查间隔：优化扩张型心肌病管理 https://news.medxy.ai/ja/ttn-mutation-screening/Medxy AIja2026-09-23T08:26:26-07:00TTN切断変異保有家族のスクリーニング間隔を個別化：拡張型心筋症管理の精緻化 https://news.medxy.ai/vi/77035-2/Medxy AIvi2026-09-23T08:26:07-07:00Cá nhân hóa khoảng thời gian sàng lọc cho các gia đình mang đột biến cắt cụt gen TTN: Tối ưu hóa việc quản lý bệnh cơ tim giãn https://news.medxy.ai/tailored-screening-intervals-for-relatives-carrying-ttn-truncations-enhancing-dilated-cardiomyopathy-management/Medxy AIen2026-09-23T08:25:48-07:00Tailored Screening Intervals for Relatives Carrying TTN Truncations: Enhancing Dilated Cardiomyopathy Management https://news.medxy.ai/zh/elderly-heart-transplant-quality/Medxy AIzh2026-09-23T08:25:07-07:00老年患者接受心脏移植或机械循环支持后的长期生活质量结局：来自 SUSTAIN-IT 研究的启示 https://news.medxy.ai/ja/77028-2/Medxy AIja2026-09-23T08:24:50-07:00高齢患者における心臓移植または機械的循環補助後の長期的なQOL（生活の質）の転帰 https://news.medxy.ai/vi/77027-2/Medxy AIvi2026-09-23T08:24:32-07:00Kết quả chất lượng cuộc sống dài hạn ở bệnh nhân cao tuổi sau ghép tim hoặc hỗ trợ tuần hoàn cơ học https://news.medxy.ai/long-term-quality-of-life-outcomes-in-older-patients-undergoing-heart-transplantation-or-mechanical-circulatory-support-insights-from-the-sustain-it-study/Medxy AIen2026-09-23T08:24:13-07:00Long-Term Quality of Life Outcomes in Older Patients Undergoing Heart Transplantation or Mechanical Circulatory Support: Insights from the SUSTAIN-IT Study https://news.medxy.ai/zh/clonal-hematopoiesis-hfpef/Medxy AIzh2026-09-23T08:23:37-07:00借助克隆性造血蛋白组学特征预测HFpEF预后 https://news.medxy.ai/ja/clonal-hematopoiesis-hfpef-2/Medxy AIja2026-09-23T08:23:17-07:00HFpEFの予後予測に挑むクローン性造血プロテオームシグネチャーの活用 https://news.medxy.ai/vi/hematopoiesis-proteome-hfpef/Medxy AIvi2026-09-23T08:22:54-07:00Khai thác dấu ấn proteome của tạo máu dòng vô tính để dự đoán tiên lượng trong HFpEF https://news.medxy.ai/leveraging-proteomic-signatures-of-clonal-hematopoiesis-to-predict-outcomes-in-hfpef/Medxy AIen2026-09-23T08:22:34-07:00Leveraging Proteomic Signatures of Clonal Hematopoiesis to Predict Outcomes in HFpEF https://news.medxy.ai/zh/balanced-crystalloids-sepsis-2/Medxy AIzh2026-09-23T07:56:50-07:00ICU前使用平衡晶体液或可降低脓毒症病死率：大型多中心队列研究揭示早期补液优势 https://news.medxy.ai/ja/balanced-crystalloids-sepsis/Medxy AIja2026-09-23T07:56:30-07:00敗血症のICU入室前輸液は平衡晶質液が有利：大規模多施設コホート研究から見えた死亡率低下 https://news.medxy.ai/vi/76996-2/Medxy AIvi2026-09-23T07:56:11-07:00Việc sử dụng dịch tinh thể cân bằng trước khi nhập vào đơn vị hồi sức tích cực (ICU) có thể làm giảm tỷ lệ tử vong do nhiễm khuẩn huyết https://news.medxy.ai/pre-icu-balanced-crystalloids-reduce-mortality-in-sepsis-insights-from-a-large-multicenter-cohort-study/Medxy AIen2026-09-23T07:55:52-07:00Pre-ICU Balanced Crystalloids Reduce Mortality in Sepsis: Insights from a Large Multicenter Cohort Study https://news.medxy.ai/zh/us-noniu-uveitis-rise/Medxy AIzh2026-09-23T07:55:12-07:00美国非感染性儿童葡萄膜炎发病率持续上升：基于十年 TriNetX 数据的临床洞见 https://news.medxy.ai/ja/76992-2/Medxy AIja2026-09-23T07:54:54-07:00米国における小児の非感染性ぶどう膜炎の発生率が上昇し続けている https://news.medxy.ai/vi/noninfectious-uveitis-kids-us/Medxy AIvi2026-09-23T07:54:33-07:00Gia tăng tỷ lệ và mức độ phức tạp lâm sàng của viêm màng bồ đào không do nhiễm trùng ở trẻ em tại Hoa Kỳ: Kết quả từ 10 năm dữ liệu TriNetX https://news.medxy.ai/rising-incidence-and-clinical-complexity-of-non-infectious-pediatric-uveitis-in-the-us-insights-from-a-decade-of-trinetx-data/Medxy AIen2026-09-23T07:54:14-07:00Rising Incidence and Clinical Complexity of Non-Infectious Pediatric Uveitis in the US: Insights from a Decade of TriNetX Data https://news.medxy.ai/zh/76987-2/Medxy AIzh2026-09-23T07:53:42-07:00视网膜母细胞瘤集中式多学科诊疗：利用远程医疗与先进眼球保留技术缩小资源匮乏地区的疗效差距 https://news.medxy.ai/ja/retinoblastoma-telemedicine/Medxy AIja2026-09-23T07:53:18-07:00遠隔医療で広がる網膜芽細胞腫の集約診療：資源制約下で生存率と眼球温存率を高める https://news.medxy.ai/vi/retinoblastoma-care/Medxy AIvi2026-09-23T07:52:52-07:00Chăm sóc u nguyên bào võng mạc tập trung, đa chuyên khoa: Thu hẹp khoảng cách kết cục bằng telemedicine và các liệu pháp bảo tồn nhãn cầu tiên tiến https://news.medxy.ai/centralized-multidisciplinary-retinoblastoma-care-closing-outcome-gaps-in-resource-limited-settings-with-telemedicine-and-advanced-globe-salvage/Medxy AIen2026-09-23T07:52:28-07:00Centralized Multidisciplinary Retinoblastoma Care: Closing Outcome Gaps in Resource-Limited Settings with Telemedicine and Advanced Globe Salvage https://news.medxy.ai/zh/lymphatic-invasion/Medxy AIzh2026-09-23T07:51:36-07:00淋巴血管侵犯：喉鳞状细胞癌独立预后标志物——来自国家队列研究的证据 https://news.medxy.ai/ja/lymphovascular-invasion/Medxy AIja2026-09-23T07:51:19-07:00喉頭扁平上皮癌における独立予後因子としてのリンパ血管侵襲：全国コホート研究からの示唆 https://news.medxy.ai/vi/76973-2/Medxy AIvi2026-09-23T07:50:57-07:00Xâm lấn mạch bạch huyết – mạch máu là một yếu tố tiên lượng độc lập đối với ung thư biểu mô tế bào vảy thanh quản https://news.medxy.ai/lymphovascular-invasion-as-an-independent-prognostic-marker-in-laryngeal-squamous-cell-carcinoma-insights-from-a-national-cohort-study/Medxy AIen2026-09-23T07:50:37-07:00Lymphovascular Invasion as an Independent Prognostic Marker in Laryngeal Squamous Cell Carcinoma: Insights from a National Cohort Study https://news.medxy.ai/zh/76967-2/Medxy AIzh2026-09-23T07:50:03-07:00早产型子痫前期期待治疗中的蛋白尿：预测妊娠结局的预后指标 https://news.medxy.ai/ja/proteinuria-preeclampsia-management/Medxy AIja2026-09-23T07:49:44-07:00早産性子癇前症の期待的管理における蛋白尿：妊娠転帰を見通す予後指標 https://news.medxy.ai/vi/proteinuria-preeclampsia/Medxy AIvi2026-09-23T07:49:24-07:00Protein niệu như một dấu ấn tiên lượng trong tiền sản giật non tháng được xử trí chờ đợi https://news.medxy.ai/proteinuria-as-a-prognostic-marker-for-pregnancy-outcomes-in-preterm-pre-eclampsia-during-expectant-management/Medxy AIen2026-09-23T07:49:04-07:00Proteinuria as a Prognostic Marker for Pregnancy Outcomes in Preterm Pre-Eclampsia During Expectant Management https://news.medxy.ai/zh/76961-2/Medxy AIzh2026-09-23T07:48:30-07:00卵巢癌一级预防中的单纯输卵管切除术：成本效益分析 https://news.medxy.ai/ja/salpingectomy-cost-effectiveness/Medxy AIja2026-09-23T07:48:12-07:00卵巣がん一次予防における単独卵管切除術：費用対効果の検討 https://news.medxy.ai/vi/76957-2/Medxy AIvi2026-09-23T07:47:51-07:00Phẫu thuật cắt vòi tử cung đơn thuần trong dự phòng cấp 1 ung thư buồng trứng: Đánh giá hiệu quả chi phí https://news.medxy.ai/standalone-salpingectomy-for-primary-ovarian-cancer-prevention-a-cost-effectiveness-analysis/Medxy AIen2026-09-23T07:47:28-07:00Standalone Salpingectomy for Primary Ovarian Cancer Prevention: A Cost-Effectiveness Analysis https://news.medxy.ai/zh/whole-grain-intake-heart-risk/Medxy AIzh2026-09-23T07:33:04-07:00全谷物摄入与心代谢风险：随机对照试验 Meta 分析证据 https://news.medxy.ai/ja/whole-grain-intake/Medxy AIja2026-09-23T07:32:43-07:00全粒穀物摂取と心血管代謝リスク：ランダム化比較試験のメタ解析からのエビデンス https://news.medxy.ai/vi/whole-grains-heart-risk-2/Medxy AIvi2026-09-23T07:32:14-07:00Ngũ cốc nguyên hạt và nguy cơ tim mạch-chuyển hóa: Bằng chứng từ phân tích tổng hợp các thử nghiệm ngẫu nhiên có đối chứng https://news.medxy.ai/whole-grain-consumption-and-cardiometabolic-risk-evidence-from-meta-analyses-of-randomized-controlled-trials/Medxy AIen2026-09-23T07:31:51-07:00Whole-Grain Consumption and Cardiometabolic Risk: Evidence from Meta-Analyses of Randomized Controlled Trials https://news.medxy.ai/zh/tenecteplase-bleeding-risk/Medxy AIzh2026-09-23T07:21:52-07:00替奈普酶溶栓后脑内出血风险：关键危险因素与临床预警模型 https://news.medxy.ai/ja/intracranial-bleeding-risk/Medxy AIja2026-09-23T07:21:32-07:00急性心筋梗塞におけるテネクテプラーゼ線溶療法後頭蓋内出血の危険因子とその低減戦略 https://news.medxy.ai/vi/hemorrhage-risk-reduction/Medxy AIvi2026-09-23T07:21:10-07:00Nhận diện và giảm thiểu các yếu tố nguy cơ xuất huyết nội sọ sau tiêu sợi huyết bằng tenecteplase trong nhồi máu cơ tim cấp https://news.medxy.ai/identifying-and-mitigating-risk-factors-for-intracranial-haemorrhage-following-tenecteplase-fibrinolysis-in-acute-myocardial-infarction/Medxy AIen2026-09-23T07:20:50-07:00Identifying and Mitigating Risk Factors for Intracranial Haemorrhage Following Tenecteplase Fibrinolysis in Acute Myocardial Infarction https://news.medxy.ai/zh/escc-pd-l1-therapy/Medxy AIzh2026-09-22T07:46:42-07:00解码细胞互作，提升食管鳞状细胞癌新辅助PD-L1阻断疗效 https://news.medxy.ai/ja/pd-l1-therapy-response/Medxy AIja2026-09-22T07:46:26-07:00食道扁平上皮癌における術前PD-L1遮断療法の反応を読み解く細胞間相互作用 https://news.medxy.ai/vi/cell-interaction-pd-l1/Medxy AIvi2026-09-22T07:46:06-07:00Giải mã tương tác tế bào để tăng cường đáp ứng ức chế PD-L1 tân bổ trợ trong ung thư biểu mô tế bào vảy thực quản https://news.medxy.ai/decoding-cellular-interactions-to-enhance-neoadjuvant-pd-l1-blockade-response-in-esophageal-squamous-cell-carcinoma/Medxy AIen2026-09-22T07:45:48-07:00Decoding Cellular Interactions to Enhance Neoadjuvant PD-L1 Blockade Response in Esophageal Squamous Cell Carcinoma https://news.medxy.ai/zh/carotid-dissection-stroke/Medxy AIzh2026-09-22T07:45:14-07:00颅颈动脉夹层后卒中复发的时间规律与形态学预测因素 https://news.medxy.ai/ja/stroke-recurrence-after-dissection/Medxy AIja2026-09-22T07:44:57-07:00頭蓋頸部動脈解離後の脳卒中再発：時間的推移と画像形態による予測因子 https://news.medxy.ai/vi/stroke-recurrence-prediction-5/Medxy AIvi2026-09-22T07:44:36-07:00Động học theo thời gian và các yếu tố hình thái dự báo tái phát đột quỵ sau bóc tách động mạch sọ-cổ https://news.medxy.ai/temporal-dynamics-and-morphological-predictors-of-stroke-recurrence-after-craniocervical-artery-dissection/Medxy AIen2026-09-22T07:44:16-07:00Temporal Dynamics and Morphological Predictors of Stroke Recurrence After Craniocervical Artery Dissection https://news.medxy.ai/zh/cushing-syndrome-lipid-worsening-2/Medxy AIzh2026-09-22T07:43:42-07:00库欣综合征术后早期血脂反常恶化：对心血管风险管理的启示 https://news.medxy.ai/ja/cushing-syndrome-lipid-worsening/Medxy AIja2026-09-22T07:43:25-07:00クッシング症候群の術後早期にみられる脂質悪化：心血管リスク評価と管理への示唆 https://news.medxy.ai/vi/cushing-syndrome-lipids/Medxy AIvi2026-09-22T07:43:05-07:00Hội chứng Cushing: Rối loạn lipid có thể nặng hơn sớm sau mổ và hàm ý nguy cơ tim mạch https://news.medxy.ai/early-lipid-deterioration/Medxy AIen2026-09-22T07:42:46-07:00Unexpected Early Postoperative Lipid Deterioration in Cushing’s Syndrome: Implications for Cardiovascular Risk and Management https://news.medxy.ai/ja/gene-editing-cvd/Medxy AIja2026-09-22T07:42:12-07:00心血管疾患における遺伝子編集療法：2026年ACC声明の重要ポイント https://news.medxy.ai/vi/76924-2/Medxy AIvi2026-09-22T07:41:38-07:00Các liệu pháp chỉnh sửa gen cho bệnh tim mạch: Những điểm chính từ Tuyên bố Khoa học năm 2026 của ACC https://news.medxy.ai/zh/cardiovascular-gene-editing/Medxy AIzh2026-09-22T07:41:02-07:00心血管疾病基因编辑治疗：2026 年 ACC 科学声明要点解读 https://news.medxy.ai/gene-editing-therapy-in-cardiovascular-disease-key-takeaways-from-the-2026-acc-scientific-statement/Medxy AIen2026-09-22T07:40:28-07:00Gene Editing Therapy in Cardiovascular Disease: Key Takeaways from the 2026 ACC Scientific Statement https://news.medxy.ai/zh/veteran-intimate-partner-violence/Medxy AIzh2026-09-22T07:34:45-07:00破解退伍军人亲密伴侣暴力医法合作落地难题：来自VA的启示 https://news.medxy.ai/ja/intimate-partner-violence/Medxy AIja2026-09-22T07:34:27-07:00親密なパートナー間暴力を経験する退役軍人への医療-法的連携を阻む壁を越えて：VAからの示唆 https://news.medxy.ai/vi/76913-2/Medxy AIvi2026-09-22T07:34:06-07:00Các vấn đề y tế liên quan đến bạo lực từ bạn tình ở cựu chiến binh https://news.medxy.ai/overcoming-barriers-to-medical-legal-partnerships-for-veterans-experiencing-intimate-partner-violence-insights-from-the-va/Medxy AIen2026-09-22T07:33:45-07:00Overcoming Barriers to Medical-Legal Partnerships for Veterans Experiencing Intimate Partner Violence: Insights from the VA https://news.medxy.ai/zh/dapirolizumab-sle-study/Medxy AIzh2026-09-22T05:41:33-07:00Dapirolizumab Pegol 改善系统性红斑狼疮疾病活动度：来自 PHOENYCS GO Ⅲ期试验及既往研究的证据 https://news.medxy.ai/ja/76203-2/Medxy AIja2026-09-22T05:41:05-07:00ダピロリズマブ・ペゴルによる全身性エリテマトーデスの疾患活動性の改善：PHOENYCS GO第III相試験および過去の研究からのエビデンス https://news.medxy.ai/vi/dapirolizumab-lupus/Medxy AIvi2026-09-22T05:40:27-07:00Dapirolizumab Pegol cải thiện hoạt tính bệnh ở lupus ban đỏ hệ thống: bằng chứng từ thử nghiệm pha 3 PHOENYCS GO và các nghiên cứu trước đó https://news.medxy.ai/dapirolizumab-pegol-improves-disease-activity-in-systemic-lupus-erythematosus-evidence-from-phase-3-phoenycs-go-trial-and-prior-studies/Medxy AIen2026-09-22T05:39:58-07:00Dapirolizumab Pegol Improves Disease Activity in Systemic Lupus Erythematosus: Evidence from Phase 3 PHOENYCS GO Trial and Prior Studies https://news.medxy.ai/zh/gvhd-prevention-evolution/Medxy AIzh2026-09-22T05:36:55-07:00alloHSCT中GVHD预防的演变：来自西班牙大型真实世界队列的启示 https://news.medxy.ai/ja/gvhd-prevention-evolution-2/Medxy AIja2026-09-22T05:36:33-07:00同種造血幹細胞移植におけるGVHD予防の進化：スペイン大規模実臨床コホートからの示唆 https://news.medxy.ai/vi/gvhd-prophylaxis-allohsct/Medxy AIvi2026-09-22T05:36:09-07:00Dự phòng GVHD trong alloHSCT đang thay đổi: Góc nhìn từ một đoàn hệ thực tế quy mô lớn tại Tây Ban Nha https://news.medxy.ai/evolving-gvhd-prophylaxis-in-allohsct-insights-from-a-large-real-world-spanish-cohort/Medxy AIen2026-09-22T05:35:47-07:00Evolving GVHD Prophylaxis in AlloHSCT: Insights from a Large Real-World Spanish Cohort https://news.medxy.ai/zh/car-t-lymphoma-risks/Medxy AIzh2026-09-22T05:35:05-07:00揭示隐藏风险：CAR T细胞治疗后T细胞淋巴瘤——罕见但真实存在的隐忧 https://news.medxy.ai/ja/car-t-therapy-risks/Medxy AIja2026-09-22T05:34:43-07:00CAR T細胞療法後に潜む稀なリスク――T細胞リンパ腫を読み解く https://news.medxy.ai/vi/car-t-cell-therapy-risks/Medxy AIvi2026-09-22T05:34:18-07:00Hiểu rõ nguy cơ: U lympho tế bào T sau liệu pháp CAR T-cell therapy — mối lo hiếm gặp nhưng có thật https://news.medxy.ai/t-cell-lymphoma-risks/Medxy AIen2026-09-22T05:33:53-07:00Unraveling the Risks: T-Cell Lymphoma After CAR T-Cell Therapy—A Rare but Real Concern https://news.medxy.ai/zh/real-world-evidence-myeloma/Medxy AIzh2026-09-22T05:33:04-07:00全球真实世界证据：多发性骨髓瘤自体干细胞移植后维持治疗可带来生存获益 https://news.medxy.ai/ja/76183-2/Medxy AIja2026-09-22T05:32:42-07:00多発性骨髄腫における自家幹細胞移植後の維持療法は、生存上の利益をもたらす可能性がある https://news.medxy.ai/vi/stem-cell-transplant-survival/Medxy AIvi2026-09-22T05:32:20-07:00Bằng chứng thực tế toàn cầu cho thấy điều trị duy trì sau ghép tế bào gốc tự thân cải thiện sống còn ở đa u tủy https://news.medxy.ai/global-real-world-evidence-shows-survival-benefit-of-maintenance-therapy-post-autologous-stem-cell-transplant-in-multiple-myeloma/Medxy AIen2026-09-22T05:31:58-07:00Global Real-World Evidence Shows Survival Benefit of Maintenance Therapy Post-Autologous Stem Cell Transplant in Multiple Myeloma https://news.medxy.ai/zh/ai-fibrosis-diagnosis/Medxy AIzh2026-09-22T05:29:36-07:00AI赋能骨髓纤维化诊断：Continuous Indexing of Fibrosis（CIF）的临床评估 https://news.medxy.ai/ja/ai-fibrosis-diagnosis-2/Medxy AIja2026-09-22T05:29:15-07:00骨髄線維化診断を高精度化：AI駆動型Continuous Indexing of Fibrosis（CIF）の臨床評価 https://news.medxy.ai/vi/bone-marrow-fibrosis-diagnosis/Medxy AIvi2026-09-22T05:28:52-07:00Nâng cao chẩn đoán xơ hóa tủy xương: Đánh giá lâm sàng chỉ số liên tục xơ hóa do AI hỗ trợ (CIF) https://news.medxy.ai/enhancing-bone-marrow-fibrosis-diagnosis-clinical-evaluation-of-ai-driven-continuous-indexing-of-fibrosis-cif/Medxy AIen2026-09-22T05:28:26-07:00Enhancing Bone Marrow Fibrosis Diagnosis: Clinical Evaluation of AI-Driven Continuous Indexing of Fibrosis (CIF) https://news.medxy.ai/zh/76169-2/Medxy AIzh2026-09-22T05:27:46-07:00靶向IL-17A驱动的PTGS2/NLRP3炎性小体活性：针对PTPN11突变型JMML的新治疗策略 https://news.medxy.ai/ja/il-17a-ptgs2-nlrp3-targeting/Medxy AIja2026-09-22T05:27:21-07:00IL-17A駆動のPTGS2/NLRP3インフラマソーム活性を標的化：PTPN11変異JMMLに対する新たな治療戦略 https://news.medxy.ai/vi/il-17a-ptpn11-treatment/Medxy AIvi2026-09-22T05:26:53-07:00Nhắm trúng trục IL-17A thúc đẩy hoạt hóa PTGS2/NLRP3: hướng điều trị mới trong JMML đột biến PTPN11 https://news.medxy.ai/targeting-il-17a-driven-ptgs2-nlrp3-inflammasome-activation-a-novel-therapeutic-approach-in-ptpn11-mutant-juvenile-myelomonocytic-leukemia/Medxy AIen2026-09-22T05:26:27-07:00Targeting IL-17A-Driven PTGS2/NLRP3 Inflammasome Activation: A Novel Therapeutic Approach in PTPN11-Mutant Juvenile Myelomonocytic Leukemia https://news.medxy.ai/zh/target-pkmyt1/Medxy AIzh2026-09-22T05:25:36-07:00靶向PKMYT1：高危del(17p)多发性骨髓瘤的潜在治疗新策略 https://news.medxy.ai/ja/pkmyt1-targeting/Medxy AIja2026-09-22T05:25:16-07:00PKMYT1を標的にする：del(17p)高リスク多発性骨髄腫に対する有望な治療戦略 https://news.medxy.ai/vi/target-pkmyt1-2/Medxy AIvi2026-09-22T05:24:52-07:00Nhắm vào PKMYT1: Chiến lược điều trị đầy hứa hẹn cho đa u tủy nguy cơ cao del(17p) https://news.medxy.ai/targeting-pkmyt1-a-promising-therapeutic-strategy-for-high-risk-del17p-multiple-myeloma/Medxy AIen2026-09-22T05:24:29-07:00Targeting PKMYT1: A Promising Therapeutic Strategy for High-Risk del(17p) Multiple Myeloma https://news.medxy.ai/zh/ibrutinib-venetoclax-lymphoma/Medxy AIzh2026-09-22T05:23:40-07:00老年及TP53突变非母细胞样套细胞淋巴瘤的一线伊布替尼联合维奈克拉：疗效与安全性 https://news.medxy.ai/ja/ibrutinib-benetoclax-treatment/Medxy AIja2026-09-22T05:23:18-07:00非芽球様マントル細胞リンパ腫に対するイブルチニブ＋ベネトクラクス一次治療：高齢者およびTP53変異例における有効性と安全性 https://news.medxy.ai/vi/ibrutinib-venetoclax-lymphoma-2/Medxy AIvi2026-09-22T05:22:53-07:00Ibrutinib phối hợp Venetoclax ở tuyến đầu cho u lympho tế bào áo thể không blastoid: Hiệu quả và độ an toàn ở người cao tuổi và bệnh nhân mang đột biến TP53 https://news.medxy.ai/first-line-ibrutinib-plus-venetoclax-in-nonblastoid-mantle-cell-lymphoma-efficacy-and-safety-in-older-adults-and-tp53-mutant-patients/Medxy AIen2026-09-22T05:22:28-07:00First-line Ibrutinib Plus Venetoclax in Nonblastoid Mantle Cell Lymphoma: Efficacy and Safety in Older Adults and TP53-Mutant Patients https://news.medxy.ai/zh/lung-transplant-kidney-impact/Medxy AIzh2026-09-22T05:21:40-07:002023年安全网政策对肺移植后肾移植的影响：移植实践与结局的早期变化 https://news.medxy.ai/ja/safety-net-impact-transplant/Medxy AIja2026-09-22T05:21:21-07:002023年safety net policyが肺移植後腎移植に与えた影響：移植診療と転帰の早期変化 https://news.medxy.ai/vi/safety-net-impact/Medxy AIvi2026-09-22T05:20:57-07:00Tác động của chính sách “safety net” năm 2023 đối với ghép thận sau ghép phổi: Những thay đổi sớm trong thực hành ghép và kết cục https://news.medxy.ai/impact-of-the-2023-safety-net-policy-on-kidney-after-lung-transplantation-early-changes-in-transplant-practices-and-outcomes/Medxy AIen2026-09-22T05:20:32-07:00Impact of the 2023 Safety Net Policy on Kidney After Lung Transplantation: Early Changes in Transplant Practices and Outcomes https://news.medxy.ai/zh/dupilumab-asthma-effects/Medxy AIzh2026-09-22T05:19:46-07:00CT视角下度普利尤单抗对中重度哮喘黏液栓动态及放射密度的影响 https://news.medxy.ai/ja/mucus-plug-dupilumab-effects/Medxy AIja2026-09-22T05:19:24-07:00中等症から重症喘息における粘液栓の変化と放射線濃度へのデュピルマブの影響：CT画像からみた解析 https://news.medxy.ai/vi/dupilumab-asthma-ct-2/Medxy AIvi2026-09-22T05:19:02-07:00Tác động của Dupilumab lên động học nút nhầy và mật độ tia X trong hen phế quản mức độ trung bình đến nặng: góc nhìn từ chẩn đoán hình ảnh CT https://news.medxy.ai/dupilumab-asthma-ct/Medxy AIen2026-09-22T05:18:37-07:00Dupilumab’s Impact on Mucus Plug Dynamics and Radiodensity in Moderate to Severe Asthma: A CT Imaging Perspective https://news.medxy.ai/zh/lung-cancer-screening-quality/Medxy AIzh2026-09-22T05:17:52-07:00远程医疗与面对面沟通下肺癌筛查共享决策质量：患者感知、证据综述与临床启示 https://news.medxy.ai/ja/76143-2/Medxy AIja2026-09-22T05:17:31-07:00遠隔医療と対面診療における肺がん検診の共有意思決定の質 https://news.medxy.ai/vi/patient-awareness-shared-decision-making/Medxy AIvi2026-09-22T05:17:02-07:00Nhận thức của bệnh nhân về chất lượng ra quyết định chung trong tầm soát ung thư phổi: so sánh giữa tư vấn từ xa và trao đổi trực tiếp, tổng hợp bằng chứng và góc nhìn lâm sàng https://news.medxy.ai/patient-perceptions-of-quality-of-shared-decision-making-for-lung-cancer-screening-in-telehealth-vs-in-person-discussions-a-synthesis-of-evidence-and-clinical-insights/Medxy AIen2026-09-22T05:16:37-07:00Patient Perceptions of Quality of Shared Decision-Making for Lung Cancer Screening in Telehealth vs In-Person Discussions: A Synthesis of Evidence and Clinical Insights https://news.medxy.ai/zh/bridging-eye-care-gap/Medxy AIzh2026-09-22T05:15:37-07:00弥合视力照护鸿沟：基于 CFIR 的美国社区成人眼筛查研究启示 https://news.medxy.ai/ja/ophthalmology-screening-challenges/Medxy AIja2026-09-22T05:15:14-07:00地域眼科スクリーニングの課題をどう越えるか：米国のCFIRガイド研究が示す示唆 https://news.medxy.ai/vi/eye-care-gap/Medxy AIvi2026-09-22T05:14:42-07:00Thu hẹp khoảng cách trong chăm sóc thị lực: Những phát hiện từ nghiên cứu định hướng CFIR về sàng lọc mắt cho người lớn dựa vào cộng đồng tại Hoa Kỳ https://news.medxy.ai/bridging-the-gap-in-vision-care-insights-from-a-cfir-guided-study-on-community-based-adult-eye-screening-in-the-u-s/Medxy AIen2026-09-22T05:14:16-07:00Bridging the Gap in Vision Care: Insights from a CFIR-Guided Study on Community-Based Adult Eye Screening in the U.S. https://news.medxy.ai/zh/76134-2/Medxy AIzh2026-09-22T05:13:30-07:00眼睑下垂综合征（Sagging Eye Syndrome）术后上斜视复发的研究 https://news.medxy.ai/ja/sagging-eye-syndrome/Medxy AIja2026-09-22T05:13:07-07:00Sagging Eye Syndromeにおける術後hypertropia再発の長期経過：知見と臨床的含意 https://news.medxy.ai/vi/76132-2/Medxy AIvi2026-09-22T05:12:41-07:00Diễn tiến dài hạn của tình trạng tái phát lác đứng lên (hypertropia) sau phẫu thuật ở bệnh nhân mắc hội chứng mắt xệ (Sagging Eye Syndrome) https://news.medxy.ai/long-term-recurrence-of-hypertropia-after-surgery-in-sagging-eye-syndrome-insights-and-implications/Medxy AIen2026-09-22T05:12:15-07:00Long-Term Recurrence of Hypertropia After Surgery in Sagging Eye Syndrome: Insights and Implications https://news.medxy.ai/zh/76129-2/Medxy AIzh2026-09-22T05:11:28-07:00超广角OCT揭示了伴有后巩膜葡萄肿的病理性近视中中央凹陷的形态及视神经乳头的特征 https://news.medxy.ai/ja/76128-2/Medxy AIja2026-09-22T05:11:04-07:00広範囲UWF-OCTが明らかにする、後部強膜ブリージアを伴う病的近視における黄斑部および視神経乳頭の形態的特徴 https://news.medxy.ai/vi/uwf-oct-central-nerve/Medxy AIvi2026-09-22T05:10:38-07:00UWF-OCT trường siêu rộng hé lộ địa hình hố trung tâm và đầu dây thần kinh thị giác khác biệt trong cận thị bệnh lý kèm phình lồi củng mạc sau https://news.medxy.ai/ultra-widefield-oct-reveals-distinct-foveal-and-optic-nerve-head-topography-in-pathologic-myopia-with-posterior-staphyloma/Medxy AIen2026-09-22T05:10:13-07:00Ultra-Widefield OCT Reveals Distinct Foveal and Optic Nerve Head Topography in Pathologic Myopia with Posterior Staphyloma https://news.medxy.ai/zh/pcv-treatment-outcomes/Medxy AIzh2026-09-22T05:09:27-07:00PCV完全消退后按需阿柏西普治疗的结局：临床综述 https://news.medxy.ai/ja/aflibercept-treatment-outcomes/Medxy AIja2026-09-22T05:09:02-07:00ポリープ状脈絡膜血管症における完全退縮後の必要時アフリベルセプト治療の転帰：臨床レビュー https://news.medxy.ai/vi/76122-2/Medxy AIvi2026-09-22T05:08:34-07:00Kết quả điều trị bằng aflibercept theo nhu cầu sau khi bệnh lý mạch hắc mạc đa giác (PCV) đã thoái lui hoàn toàn https://news.medxy.ai/outcomes-of-as-needed-aflibercept-treatment-after-complete-regression-in-polypoidal-choroidal-vasculopathy-a-clinical-review/Medxy AIen2026-09-22T05:08:02-07:00Outcomes of As-Needed Aflibercept Treatment After Complete Regression in Polypoidal Choroidal Vasculopathy: A Clinical Review https://news.medxy.ai/zh/76119-2/Medxy AIzh2026-09-22T05:07:08-07:00舒马曲坦（Susetiridine）能减少头颈部手术后阿片类药物使用 https://news.medxy.ai/ja/suzoterijin-opioid-use/Medxy AIja2026-09-22T05:06:48-07:00頭頸部手術後のオピオイド使用を抑えるスゼトリジンの役割：後ろ向きコホート解析 https://news.medxy.ai/vi/opioid-reduction-surgery/Medxy AIvi2026-09-22T05:06:25-07:00Suzetrigine giúp giảm sử dụng opioid sau phẫu thuật đầu cổ như thế nào? Phân tích đoàn hệ hồi cứu https://news.medxy.ai/suzetrigines-role-in-reducing-opioid-use-after-head-and-neck-surgery-a-retrospective-cohort-analysis/Medxy AIen2026-09-22T05:06:03-07:00Suzetrigine’s Role in Reducing Opioid Use After Head and Neck Surgery: A Retrospective Cohort Analysis https://news.medxy.ai/zh/rf-ablation-thyroid-nodules/Medxy AIzh2026-09-22T05:05:19-07:00射频消融：甲状腺叶切除术后甲状腺结节的微创替代方案 https://news.medxy.ai/ja/radiofrequency-ablation-options/Medxy AIja2026-09-22T05:05:00-07:00葉切除後の甲状腺結節に対する低侵襲選択肢：Radiofrequency Ablationの有用性 https://news.medxy.ai/vi/radiofrequency-ablation/Medxy AIvi2026-09-22T05:04:38-07:00Đốt sóng cao tần: Lựa chọn ít xâm lấn cho nhân giáp sau cắt thùy giáp https://news.medxy.ai/radiofrequency-ablation-a-minimally-invasive-alternative-for-thyroid-nodules-post-lobectomy/Medxy AIen2026-09-22T05:04:18-07:00Radiofrequency Ablation: A Minimally Invasive Alternative for Thyroid Nodules Post-Lobectomy https://news.medxy.ai/zh/cvemp-vhit-discrepancy/Medxy AIzh2026-09-22T05:03:37-07:00cVEMP与后半规管vHIT为何常不一致：1770只耳研究揭示前庭诊断新视角 https://news.medxy.ai/ja/vemp-vhit-comparison/Medxy AIja2026-09-22T05:03:13-07:00頸部VEMPと後半規管vHITは本当に同じ機能を見ているのか？―1770耳の解析から見えた前庭診断の新たな示唆 https://news.medxy.ai/vi/cvemp-vhit-difference/Medxy AIvi2026-09-22T05:02:48-07:00Sự phân ly chức năng giữa cVEMP cổ và vHIT ống bán khuyên sau: gợi ý mới cho chẩn đoán tiền đình trên 1770 tai không chọn lọc https://news.medxy.ai/functional-dissociation-of-cervical-vemp-and-posterior-canal-vhit-implications-for-vestibular-diagnostics-in-1770-unselected-ears/Medxy AIen2026-09-22T05:02:24-07:00Functional Dissociation of Cervical VEMP and Posterior Canal vHIT: Implications for Vestibular Diagnostics in 1770 Unselected Ears https://news.medxy.ai/zh/thyroid-compression-symptoms-2/Medxy AIzh2026-09-22T05:01:37-07:00甲状腺压迫性症状：优化诊断与治疗以改善预后 https://news.medxy.ai/ja/76103-2/Medxy AIja2026-09-22T05:01:16-07:00甲状腺による圧迫症状：予後改善に向けた診断と治療の最適化 https://news.medxy.ai/vi/thyroid-compression-symptoms/Medxy AIvi2026-09-22T05:00:51-07:00Triệu chứng chèn ép do tuyến giáp: Tối ưu hóa chẩn đoán và điều trị để cải thiện kết cục https://news.medxy.ai/thyroid-compressive-symptoms-optimizing-diagnosis-and-management-for-improved-outcomes/Medxy AIen2026-09-22T05:00:25-07:00Thyroid Compressive Symptoms: Optimizing Diagnosis and Management for Improved Outcomes